Capital Power Secures 1 GW Supply of Responsibly Produced, Ultra-Low Carbon First Solar Modules
Series 6 Plus thin film modules to power US and Canada projects, with deliveries from…
ISP
Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia
Encouraging antileukemic activity seen with NKX101 in patients with AML, including several with high-risk features,…
Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia
Encouraging antileukemic activity seen with NKX101 in patients with AML, including several with high-risk features,…
Black Diamond Therapeutics Announces Initial Dose Escalation Data Demonstrating Anti-Tumor Activity of BDTX-1535 in Non-Small Cell Lung Cancer Patients Across Multiple EGFR Mutation Families
BDTX-1535, an epidermal growth factor receptor (EGFR) MasterKey inhibitor, demonstrates clinical proof of activity for…
Black Diamond Therapeutics Announces Initial Dose Escalation Data Demonstrating Anti-Tumor Activity of BDTX-1535 in Non-Small Cell Lung Cancer Patients Across Multiple EGFR Mutation Families
BDTX-1535, an epidermal growth factor receptor (EGFR) MasterKey inhibitor, demonstrates clinical proof of activity for…
Agile Therapeutics Announces the Availability of Twirla® to MMCAP Infuse Members
Twirla (levonorgestrel and ethinyl estradiol) transdermal system will be made available nationwide to members of…
Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™
Presentations highlight preclinical and clinical advancements of bexotegrast program in primary sclerosing cholangitis SOUTH SAN…
TransCode Therapeutics Announces Publication of New Data Supporting the Use of TTX-MC138 for the Treatment of Metastatic Breast Cancer
BOSTON, June 22, 2023 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology…
Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
Vamorolone is Currently Under Review with the FDA (PDUFA Date of October 26, 2023) for…
bit.bio is Industrialising Human Cell Manufacturing, Unleashing the Potential of Synthetic Biology for Reproducible Research and Affordable Regenerative Medicines
Data presented at International Society for Stem Cell Research conference shows unparalleled level of consistency…
Editas Medicine Announces Pricing of Offering of Common Stock
CAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage…
Intellia Therapeutics Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (HAE)
Extended Phase 1 data reinforce the potential of NTLA-2002 to be a functional cure for…
Nkarta Presents NKX019 Clinical Data at the European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma
7 of 10 r/r NHL patients achieved complete response (70% CR rate) following treatment with…
Wolters Kluwer Webinar Brings Together Nursing Leaders to Discuss New Technologies
Webinar will examine the influence of ChatGPT, generative AI and more on nursing education WALTHAM,…
Successful Primary Engraftment of Trem-cel in First Five AML Patients Demonstrates Promise of Vor Bio’s Platform
Patients transplanted with trem-cel achieved primary neutrophil engraftment and high levels of myeloid donor chimerism….
Editas Medicine Announces Positive Initial EDIT-301 Safety and Efficacy Data from the First Four Patients Treated in the RUBY Trial and the First Patient Treated in the EdiTHAL Trial
EDIT-301 was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and…
TransCode Therapeutics Announces Pricing of $7 Million Public Offering
BOSTON, June 06, 2023 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an…
Editas Medicine to Host Virtual Event to Discuss EDIT-301 Clinical Data from the RUBY Trial for Severe Sickle Cell Disease and the EDITHAL Trial for Transfusion-dependent Beta Thalassemia
CAMBRIDGE, Mass., June 06, 2023 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome…
Editas Medicine to Host Virtual Event to Discuss EDIT-301 Clinical Data from the RUBY Trial for Severe Sickle Cell Disease and the EDITHAL Trial for Transfusion-dependent Beta Thalassemia
CAMBRIDGE, Mass., June 06, 2023 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome…
Intellia Therapeutics Announces Retirement of Jean-François Formela, M.D. From its Board of Directors
CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage…